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ttp://dx.doi.org/10.1016/j.ajpath.2013.10.005A stable and persistent Hepatitis C virus (HCV) replication cell culture model was developed to examine
clearance of viral replication during long-term treatment using interferon-a (IFN-a), IFN-l, and ribavirin
(RBV). Persistently HCV-infected cell culture exhibited an impaired antiviral response to IFN-aþRBV
combination treatment, whereas IFN-l treatment produced a strong and sustained antiviral response that
cleared HCV replication. HCV replication in persistently infected cells induced chronic endoplasmic retic-
ulum (ER) stress and an autophagy response that selectively down-regulated the functional IFN-a receptor-
1 chain of type I, but not type II (IFN-g) or type III (IFN-l) IFN receptors. Down-regulation of IFN-a
receptor-1 resulted in defective JAKeSTAT signaling, impaired STAT phosphorylation, and impaired nuclear
translocation of STAT. Furthermore, HCV replication impaired RBV uptake, because of reduced expression of
the nucleoside transporters ENT1 and CNT1. Silencing ER stress and the autophagy response using chemical
inhibitors or siRNA additively inhibited HCV replication and induced viral clearance by the IFN-aþRBV
combination treatment. These results indicate that HCV induces ER stress and that the autophagy response
selectively impairs type I (but not type III) IFN signaling, which explains why IFN-l (but not IFN-a)
produced a sustained antiviral response against HCV. The results also indicate that inhibition of ER stress
and of the autophagy response overcomes IFN-aþRBV resistance mechanisms associated with HCV
infection. (Am J Pathol 2014, 184: 214e229; http://dx.doi.org/10.1016/j.ajpath.2013.10.005)Supported by grants from NIH (CA127481, CA089121, and AI103106),
by funds from the Louisiana Cancer Research Consortium (LCRC), and by
bridge funding from Tulane University Health Sciences Center (S.D.).Hepatitis C virus (HCV) infects more than 170million people
worldwide and is one of the leading causes of chronic liver
disease, liver cirrhosis, and hepatocellular carcinoma in the
United States.1,2 Combination therapy using interferon-a
(IFN-a), ribavirin (RBV), and a protease inhibitor is the
current standard of care for HCV genotype 1 infection.3,4
Although this triple combination therapy has signiﬁcantly
improved the sustained virological response of chronic HCV
1a infection, the treatment response has not improved
signiﬁcantly among prior nonresponders to pegylated inter-
feron and RBV.5,6 Several studies have suggested that the
risk of HCV-induced liver cirrhosis and hepatoma is sub-
stantially reduced in patients who clear HCV infection and
achieve a sustained virological response.7,8 The poor sus-
tained virological response with triple therapy in patients
who are nonresponders to the combination of IFN-a and
RBV (IFN-aþRBV) is a major unsolved problem in treatingstigative Pathology.
.chronic hepatitis C. The mechanism of HCV resistance under
these conditions is not well understood. A better under-
standing of the mechanism of HCV clearance by IFN-a and
RBV could lead to improvements in treatment for such pa-
tients and reduce the burden of liver cirrhosis and hepatoma.
The availability of highly efﬁcient cell culture systems
suitable for study of HCV has enabled molecular studies of
IFN-a antiviral mechanisms against HCV. A series of
publications from our laboratory with others have veriﬁed
that the JAKeSTAT pathway induced by IFN-a is critical
for the HCV antiviral mechanism in cell culture models.9e11
Studies performed over the last several years indicate that
IFN-a signaling is controlled by a number of factors,
HCV Infection Impairs IFN-a Signalingincluding suppressor of cytokine signaling (SOCS) family
members SOCS1 and SOCS3, ubiquitin-speciﬁc peptidase
18 (USP18), the protein inhibitor of activated STAT1
(PIAS1), and protein phosphatase 2A (PP2A).12 Although
RBV is used in combination with IFN-a to treat patients with
HCV infection, the mechanisms by which many patients
develop resistance to RBV are not well understood. One
report indicated that reduced RBV uptake by HCV-infected
cells contributed to an impaired antiviral response.13 How-
ever, no previous systematic studies have investigated how
the IFN-a and RBV synergistic antiviral mechanisms are
impaired during chronic HCV infection.
Recent clinical studies indicate that the overall success of
triple combination therapy depends on the initial patient
response to combined IFN-aþRBV treatment and on host
genetic polymorphisms of the IFN-l gene (IFNL3; alias IL-
28B).14,15 The importance of the IL-28B genotype and the
IFN-l system in the clearance of HCV replication is not
well understood. Elucidating the factors determining HCV
clearance by type I and type III IFNs and RBV, using a
stable and persistently HCV-infected cell culture system,
should open new approaches to improving the sustained
virological response among nonresponders.
We developed a stable and persistently HCV-infected Huh-
7.5 cell culture system to examine the contribution of viral and
host-cell factors in the mechanisms of HCV clearance induced
by long-term antiviral treatment using IFN-aþRBV or IFN-l.
Here, we show that HCV replication in the persistently HCV-
infected cell culture induces endoplasmic reticulum (ER) stress
and an autophagy response that selectively impairs IFN-
aþRBVemediated viral clearance. On the other hand, our
results indicate that exogenous IFN-l treatment leads to HCV
clearance in persistently HCV-infected cells in culture.
Furthermore, our results suggest that targeting chronic ER
stress and HCV-induced autophagy may overcome IFN-a and
RBV resistance mechanisms in chronic HCV infection.
Materials and Methods
Cell Lines, Infectious Clones, Plasmids, Antibodies,
and Chemicals
Huh-7 and Huh-7.5 human hepatocellular carcinoma cells, a
kind gift from Charles M. Rice (Rockefeller University,
New York), were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM; Life Technologies, Carlsbad, CA) and
supplemented with nonessential amino acids, sodium py-
ruvate, and 10% (v/v) fetal bovine serum (FBS). Huh-7 cells
with defective JAKeSTAT signaling (cell line R-24-1),
described previously,9 and a human ﬁbroblast cell line (2H-
11) were maintained as above. Cells were grown at 37C in a
5% CO2eenriched atmosphere within a humidiﬁed incu-
bator. TheRenilla luciferase reporterebased pJFH-DV3-Rluc
clone used in our experiment has been described previously.16
The following were obtained commercially: IFN-a (EMD
Merck, Billerica, MA); IFN-l (IL-29; PeproTech, Rocky Hill,The American Journal of Pathology - ajp.amjpathol.orgNJ); Torin 1 (Selleck Chemicals, Houston, TX); RBV, Acri-
dine Orange, 4-phenylbutyric acid (PBA), thapsigargin (TG),
and hydroxychloroquine (HCQ) (Sigma-Aldrich, St. Louis,
MO); [3H]cytidine, [3H]RBV (Moravek Biomedicals, Brea,
CA); and plasmids p5xATF6-GL3, pSTAT1-GFP (Addgene,
Cambridge, MA), pSTAT2-GFP (a gift from Hansjörg
Hauser, GBF-National Research Institute for Biotechnology,
Braunschweig, Germany), and pISRE-luciferase (provided by
Stephen Goodbourn, St. George’s Hospital and Medical
School, University of London, London, UK). siRNAs against
PERK, IRE1a, ATF6, and ATG7 (Life Technologies) were as
described previously.17 Synthetic siRNAs targeted to 50UTRof
HCV genome (si321 and si359) were from Life Technolo-
gies.18 Antibodies speciﬁc for IFNAR1 (Biogen Idec, Cam-
bridge, MA), IFNAR2, IFNGR1, CNT1, ATF6 (Santa Cruz
Biotechnology, Santa Cruz, CA), IFN-l receptor IL10Rb
(R&D Systems, Minneapolis, MN), b-actin, GAPDH, p-
STAT1, STAT1, p-STAT2, STAT2, LC3, p62, beclin 1, BiP,
IRE1a, p-eIF2a, PERK, ATG7 (Cell Signaling Technology,
Danvers, MA), ENT1 (Abgent, San Diego, CA), HCV Core
protein (Thermo Fisher Scientiﬁc, Waltham, MA), and anti-
Renilla luciferase (EMD Merck, Billerica, MA) were obtained
from the respective manufacturers.17,18
Development of a Stable Infected Huh-7.5 Cell Culture
System
Huh-7.5 cells were transfected with 20 mg of in vitro tran-
scribed HCV RNA prepared from clone pJFH-DV3-Rluc
(HCV genotype 2a), and culture-derived infectious HCV
stocks were prepared from the supernatants of Huh-7.5 cells
using a protocol described previously.19 In brief, Huh-7.5 cells
were infected with multiplicity of infection (MOI) 0.1 JFH-
DV3-Rluc virus overnight, and on the next day the infected
culture was washed with PBS and then incubated with 10 mL
of DMEM containing 10% FBS (v/v). Infected Huh-7.5 cells
were cultured long-term by splitting at a 1:10 ratio at 6-day
intervals. Replication of HCV in the infected cell culture at
each interval was conﬁrmed by measuring the Renilla lucif-
erase activity or the HCV RNA level by RT-qPCR.
Interferon and RBV Treatment and HCV Quantiﬁcation
To calibrate and compare the biological activity and anti-
viral efﬁcacy of IFN-a and IFN-l (for which concentration
is expressed in different units), we ﬁrst determined the 90%
inhibitory concentration (IC90) of these two cytokines. Huh-
7.5 cells were infected with MOI Z 0.1 JFH-DV3-Rluc
virus overnight. The next day, the infective virus was
removed, and cells were treated with different concentra-
tions of IFN-a or IFN-l. After 72 hours, the IC90 was
determined to be 100 IU/mL for IFN-a and 10 ng/mL for
IFN-l (as discussed further under Results). In the next step,
we compared the treatment response of IFN-a and IFN-l in
the HCV-infected cell culture model. Huh-7.5 cells were
infected with MOI Z 0.1 JFH-DV3-Rluc reporter virus215
Chandra et alovernight. In one set of experiments, IFN-a and RBV were
added after 48 hours of infection, to determine the antiviral
effect in a cell culture system. After 48 hours of infection, cells
were treated with 2.5 IC90, 5 IC90, or 10 IC90 IFN-a or
IFN-l, or with 40mg/mLRBVor 2.5 IC90þ 40mg/mL IFN-
aþRBV. After 72 hours, half of the cells were used for
measuring the antiviral effect and the remaining cells were
seeded for a second round of treatment. The antiviral effects of
IFN-a, IFN-l, RBV alone, and the IFN-aþRBV combination
weremeasuredat 3-day intervals. In another set of experiments,
infected cells were cultured for 1 week to increase the level of
viral replication.Onday 8, cellswere treatedwithRBVor IFN-
aþRBV as described. The sustained antiviral effect was
measured for an extended time period. Five consecutive
treatments were given at 6-day intervals for up to 37 days.
Antiviral activity was assessed after each treatment. Luciferase
activity of cell lysates was measured using a Renilla luciferase
assay system kit (Promega, Madison, WI). Total protein con-
centration of the lysate was measured using a NanoDrop
spectrophotometer (Thermo Fisher Scientiﬁc). Renilla lucif-
erase activity was normalized to protein concentration.
RT-qPCR
An RT-qPCR assay for HCV quantiﬁcation was performed
according to a protocol described previously.18 In brief, 2
mg of cellular RNA or total RNA from 1 mL of conditioned
culture medium was used to amplify the 50UTR of the HCV
genome using sense primer 50-TCTTCACGCAGAAAGC-
GTCTA-30 (60e80; HCV/S) and antisense primer 50-CGG-
TTCCGCAGACCACTATG-30 (157e138; HCV/AS). The
probe 50-/56-FAM/TGAGTGTCG/ZEN/TGCAGCCTCCA-
GGA/3IBkFQ/-30 (Integrated DNA Technologies, Coral-
ville, IA), labeled at the 50 ends with a 6-carboxyﬂuorescein
(FAM) ﬂuorophore reporter molecule and ZEN-Iowa Black
FQ (IBFQ) double quenchers, was used to reduce the
background and increase signal. The RT-qPCR assay was
performed in 20 mL containing 10 mL of iQ supermix (Bio-
Rad Laboratories, Hercules, CA), 0.25 mmol/L of each
primer and probe, and 4 mL of cDNA product obtained from
the reverse-transcription reaction. The ampliﬁcation was
performed using a standard program: 48C for 30 minutes
and 95C for 10 minutes, followed by 45 cycles of 95C for
15 seconds (denaturation) and 60C for 1 minute (annealing
and extension). HCV cDNA standards were used, starting at
1  109 copies of virus and decreasing in 10-fold serial
dilutions. Ampliﬁcation, data acquisition, and analysis were
performed using a CFX96 real-time PCR system with CFX
Manager software version 1.0 (Bio-Rad Laboratories).
Western Blot Analysis
Cells were lysed in ice-cold radioimmunoprecipitation assay
buffer. Total protein content in the lysate was quantiﬁed
using a protein assay kit (Bio-Rad Laboratories). An equal
amount of protein from each sample was mixed in 4 SDS216loading buffer. Proteins were separated using NuPAGE 12%
gels (Life Technologies) and then were transferred onto a
nitrocellulose membrane (GE Healthcare, Little Chalfont,
UK). The membrane was blocked with ﬁltered blocking so-
lution [10 mmol/L Tris-buffered saline (pH 7.4), 0.1% (v/v)
Tween 20, 5% (v/v) nonfat dried milk] for 2 hours with gentle
shaking at room temperature. Next, the membrane was
washed with 10 mmol/L Tris-buffered saline (pH 7.4) con-
taining 0.1% Tween 20 (v/v), three times for 5 minutes each.
The primary antibody was diluted (according to the manu-
facturer’s instructions) in blocking reagent [10 mmol/L Tris-
buffered saline (pH 7.4), 0.1% Tween 20 (v/v), 5% nonfat
dried milk (w/v) or 5% bovine serum albumin (w/v)], added
to the membrane, and incubated at 4C overnight with gentle
shaking. The next day, the membrane was washed with wash
buffer three times for 5 minutes each. The horseradish per-
oxidaseeconjugated secondary antibody was diluted in
blocking reagent [10 mmol/L Tris-buffered saline (pH 7.4),
0.1% Tween 20 (v/v), 5% nonfat dried milk (w/v)], added to
the membrane, and incubated at room temperature for 2 hours
with gentle shaking. The membrane was again washed with
wash buffer three times for 5 minutes each. Enhanced
chemiluminescence ECL detection reagent (GE Healthcare)
was then added to the membrane according to the manufac-
turer’s instructions. The membrane was then exposed to
chemiluminescence ﬁlm (GE Healthcare).
Nuclear Translocation Assay
Naïve or persistently infected Huh-7.5 cells were split in a 12-
well cell culture plate (Thermo Fisher Scientiﬁc) at a density of
2  104 cells per well. After 20 hours, cells were transfected
with 0.2 mg of STAT1-GFP or STAT2-GFP plasmid DNA
using FuGENE 6 (Roche Diagnostics, Indianapolis, IN)
transfection reagent. At 48 hours, both pSTAT1-GFP and
pSTAT2-GFP transfected cells were treated with 500 IU/mL
IFN-a (5  IC90). The translocation of GFP was monitored
using ﬂuorescence microscopy (Olympus IX70 microscope);
imageswere captured using anOlympusDP-71 digital camera.
RBV Uptake
RBV uptake into persistently HCV-infected cells was
measured using a previously described protocol,13 withminor
modiﬁcations. Infected cells were harvested after trypsine
EDTA treatment and were washed twice using DMEM
growth medium supplemented with 10% FBS. Equal
numbers of infected cells (1 106) were resuspended in 1mL
of growth medium in sterile polystyrene, round-bottom tubes
with caps. RBVuptake assayswere initiated by the addition of
100 mL of cell culture medium supplemented with either 7.2
mL of 5 mmol/L [3H]RBV or 12.5 mL of [3H]cytidine in a CO2
incubator at 37C with continuous shaking. After 30 minutes
of incubation, cells were treated with 1 mL of ice-cold PBS
andwere placed on ice for 5minutes to stop the reaction. After
this step, cells were washed twice with 1 mL of ice-cold PBS.ajp.amjpathol.org - The American Journal of Pathology
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[10mmol/L Tris-HCl (pH 8.0), 10mmol/LNaCl, 1.5mmol/L
MgCl2, and 0.1% NP-40 (v/v)]. A 40-mL aliquot of soluble
protein lysate was mixed with 1 mL of scintillation ﬂuid,
and radioactivity was measured using a liquid scintillation
analyzer (PerkinElmer, Walton, MA). Uptake values were
expressed as counts per minute per cell.
Evaluation of ER Stress and Autophagy Response in
HCV Cell Culture
Activity of the ATF6 protein, which functions as an ER stress
sensor, was measured in HCV-infected culture. Initially, Huh-
7.5 cells were infected with MOIZ 0.1 JFH-DV3-Rluc virus
overnight. The next day, infectious cell culture supernatantwas
removed and p5xATF6-GL3 plasmid containing the ﬁreﬂy
reporter gene was transfected with FuGENE 6 (Roche Di-
agnostics) transfection reagent in both uninfected and infected
Huh-7.5 cells. ATF6eﬁreﬂy luciferase activity was measured
in a kinetic manner for 10 days. In the same lysates, HCVe
Renilla luciferase activity was also measured, to conﬁrm HCV
infection (data not shown). The autophagy response due to
HCV replication in the culture was assessed by measuring the
autophagy-related hallmark proteins LC3, p62, and beclin 1 by
Western blotting and immunohistochemistry. A published
protocol20 was followed to visualize acidic autophagolyso-
some formation by ﬂuorescence microscopy, using Acridine
Orange staining. In brief, cells were stained in DMEM con-
taining 5 mg/mL Acridine Orange for 15 minutes. The cells
werewashed three times in PBS and examined by ﬂuorescence
microscopy. The color change of Acridine Orange from green
to red was monitored under an Olympus IX70 microscope
(40 objective lens) and aDP-71 digital camera. The exposure
time was 200 ms. The manufacturer’s cell imaging software
was used for the acquisition of microscopic images.
Electron Microscopy
Uninfected and persistently infected Huh-7.5 cells were pel-
leted, rinsed, and resuspended in 3% glutaraldehyde ﬁxative
(Sigma-Aldrich). Cell pellets were postﬁxed in 1% osmium
tetroxide and dehydratedwith an ethyl alcohol series. Samples
were inﬁltrated and embedded in eponate 12 resin and poly-
merized at 60C for 24 hours. Thin sections (70 nm thickness)
of the samples were placed on copper grids. Cells were
examined using a G2 F30 Tecnai transmission electron mi-
croscope (TEM) at 200 kV (FEI, Hillsboro,OR). The numbers
of autophagic vacuoles per ﬁeld per cell were counted.
Immunostaining for HCV Core
Infected Huh-7.5 cells with or without IFN treatment were
mounted onto a glass slide via the cytospin centrifugation
method. The cells were washed twicewith 10mmol/L PBS (pH
7.4) for 5minutes. The cells were ﬁxed in chilled acetone for 15
minutes and then permeabilized by treatment with RevealThe American Journal of Pathology - ajp.amjpathol.orgDecloaker RTU pretreatment reagent (RV 100; Biocare Med-
ical, Concord, CA) for 25 minutes at its boiling point. Slides
were then cooled to room temperature for 25minutes. Blocking
was performed using Background Sniper blocking reagent
(BS966; Biocare Medical) for 10 minutes at room temperature.
The cells were incubated with monoclonal anti-Core antibody
(Pierce hepatitis C virus Core antigen-speciﬁc mouse mono-
clonal antibody,Ma1-080; Thermo Fisher Scientiﬁc, Rockford,
IL) diluted 1:200 with DaVinci Green diluent (PD900; Biocare
Medical) for 1 hour at room temperature. After the primary
antibody incubation, the cells were washed three times in Tris-
buffered saline (pH 8.0), and incubated with MACH 4 mouse
probe (UP534; BiocareMedical) for 10minutes. The cells were
then incubated with MACH 4 horseradish peroxidase polymer
(MRH534; Biocare Medical) for 30 minutes, and washed with
Tris-buffered saline three times. Next, the cells were treated
with diaminobenzidine chromogen (Dako, Carpinteria, CA) for
5 minutes. The slides were counterstained with hematoxylin for
30 seconds and Tacha’s bluing solution (HTBLU; Biocare
Medical) for 30 seconds and then were dehydrated, mounted,
and observed by light microscopy.
Cell Surface Expression and Quantiﬁcation of IFN
Receptors
Cell surface expression of IFN-a, IFN-g, and IFN-l re-
ceptors (IFNAR1, IFNgR1, and IL10Rb, respectively) in
uninfected and persistently infected cells was examined at
4C using a published protocol.21 1  106 Huh-7 cells were
washed in ice-cold DMEM containing 1% (v/v) FBS. Cells
were incubated for 1 hour at 4Cwith primary antibody (1:25
dilution) speciﬁc for IFN-a, IFN-g, or IFN-l receptors with
gentle shaking. Cells were then washed once with DMEM
containing 1% (v/v) FBS and then incubated with Alexa
Fluor 488 (green)econjugated secondary antibody (dilution
of 1:50) (Life Technologies) for 30 minutes at 4C with
shaking. Finally, cells were washed twice with DMEM
containing 1% (v/v) FBS and an aliquot of cell suspension
was examined for IFN-receptor expression by confocal mi-
croscopy at the Tulane National Primate Center (Covington,
LA). The surface GFP expressions of the IFN-a, IFN-g, or
IFN-l receptors were quantiﬁed by ﬂow cytometric analysis.
Three independent experiments were performed.
Sorting of IFN-a Sensitive and Resistant HCV-Infected
Cells by Flow Cytometry
Persistently infected Huh-7.5 cells (45 days of infection)
that did not clear HCV replication after two consecutive
treatments with 2.5  IC90 IFN-a were separated by ﬂow
cytometry after intracellular HCV Core protein staining.
Infected cells were ﬁxed for 10 minutes with 2% (w/v)
paraformaldehyde in PBS. After this step, cells were washed
once using DMEM containing 5% (v/v) FBS, and then were
treated with 1 mL of 1 ﬂuorescence-activated cell sorting
(FACS) permeabilizing solution [0.5% (w/v) saponin in217
Figure 1 Establishment of a stable and persistently infected HCV replica-
tion system in Huh-7.5 cells. Cells were infected with MOIZ 0.1 JFH-DV3-Rluc
virus overnight. The infected cells were cultured in DMEM with 10% (v/v) FBS,
with passage every 6 days. A: The Renilla luciferase activity of infected cell ly-
satesmeasured up to 38days in culture indicatesHCV replication after infection.
The human ﬁbroblast cell line (2H-11) was used as a negative control. B: HCV
RNA level in the infected culture over 38days. Thedotted line indicates the limit
of detection of the assay.C: HCV CoreandNS5AeRlucprotein levels by timeafter
infection, measured by Western blotting, with b-actin as a loading control. D:
Immunocytochemical staining of uninfected (HCV) and infected (HCVþ) Huh-
7.5 cells, using a monoclonal antibody speciﬁc for HCV Core protein; positive
staining is reddish-brown. E: HCV Core protein was detected by immunoﬂuo-
rescence; the presence of HCVþ cells was conﬁrmed by ﬂow cytometric analysis
and is reported as the percentage of HCVþ cells in the infected culture. F:
Infectivity assay of culture supernatants was performed using three different
hepatic cell lines (R-24-1 is an IFN-aeresistant Huh-7 cell line) and one non-
hepatic cell line (2H-11). Cells were infected with 1 mL of MOIZ 0.1 culture
supernatant overnight, washed, and then cultured with growth medium. Cells
were passaged at 6-day intervals, and Renilla luciferase activity of cell lysates
was measured. Data are expressed as means SD. Original magniﬁcation:20
(D);40 (E). FITC, ﬂuorescein isothiocyanate; RLU, relative light units.
Chandra et alPBS] at room temperature. Cells were then incubated with a
monoclonal antibody to HCV Core protein for 60 minutes at
room temperature. After this step, cells were washed twice
with DMEM containing 5% (v/v) FBS and incubated with
Alexa Fluor 488econjugated secondary antibody (1:50)
(Life Technologies) diluted in DMEM containing 5% (v/v)
FBS. Finally, cells were washed twice, pelleted, resus-
pended in PBS, and analyzed by FACS. IFN-aesensitive
(HCV Core-) and resistant (HCV Coreþ) cells were sepa-
rated by ﬂow sorting on a FACSAria system (BD Biosci-
ence, San Jose, CA). Sorted cells were lysed, and expression
levels of IFNAR1 in IFN-aesensitive and resistant cells
were determined by Western blotting.
Statistical Analysis
All measurements were made at least in triplicate (n Z 3).
To compare means within groups, we performed one-factor
analysis of variance using GraphPad Prism software version
5.01 (GraphPad Software, La Jolla, CA). We assumed that
all measurements have normal probability distributions,
which is expected for these types of data. When the overall
P value for the analysis of variance analysis was signiﬁcant
(P < 0.05), we applied Dunnett’s post hoc test to compare
control samples with experimental samples.22 For compar-
isons between multiple groups, each analyzed with analysis
of variance, we used the Bonferroni correction23 to deter-
mine a revised cutoff for statistical signiﬁcance that gives a
combined 5% type I error probability.
Results
Development of a Stable and Persistently Infected
Huh-7.5 Cell Culture System
Huh-7.5 cells were infected with JFH-DV3-Rluc and then
cultured continuously by splitting cells at 6-day intervals.
HCV replication was conﬁrmed by the measurement of
Renilla luciferase activity of the cell lysate, as well as by
determining HCV RNA titer using RT-qPCR (Figure 1, A
and B). On day 3, the titer of HCV in the infected culture
was 102 copies/mg of cellular RNA, which gradually
increased to 107 copies/mg of cellular RNA after 38 days.
These results were also conﬁrmed by measuring the
expression of HCV Core protein and HCV NS5AeRenilla
luciferase fusion protein by Western blot analysis. The
expression of HCV Core protein and NS5AeRenilla lucif-
erase fusion protein in the infected cells increased over 38
days (Figure 1C), and these results were veriﬁed by quan-
tiﬁcation of band intensity (Supplemental Figure S1).
The number of cells infected with HCV in the culture was
determined by measuring Core protein expression by immu-
nocytochemical staining (Figure 1D). Using a ﬂuorochrome-
labeled secondary antibody, the percentage of HCVCoreþ cells
was quantiﬁed using ﬂow cytometric analysis. Approximately
70% of the cells in the culture were infected with HCV218(Figure 1E). The persistently infected cells secreted infectious
virus particles as conﬁrmed by a multicycle infectivity assay
using three different liver-derived cell lines and one none
liver-derived cell line. Huh-7 cells with defective JAKeSTAT
signaling (R-24-1) supported high-level HCV replication,
compared with other Huh-7 cells. The human ﬁbroblast cell line
2H-11 used as a negative control did not support HCV infection
(Figure 1F). The viral titer ofHuh-7.5 infected cells passaged for
13 rounds (P13) was much higher, compared with the original
JFH1 that has not been passaged (P0) (Supplemental Figure S2).
Persistently Infected HCV Cell Culture Is Partially
Responsive to IFN-a and RBV but Completely
Responsive to IFN-l
The IC90 of IFN-a and IFN-l was determined, to allow
calibration and comparison of their biological activity. Weajp.amjpathol.org - The American Journal of Pathology
Figure 2 HCV replication in persistently infected Huh-7.5 cell culture is partially resistant to IFN-a and RBV but not to IFN-l treatment. A: Infection
kinetics of culture supernatant (without passage) in Huh-7.5 cells was determined (MOI Z 0.1) by measuring the Renilla luciferase activity, normalized to
total protein. B: Levels of IFN-a and IFN-l receptors (IFNAR1 and IFNlR) in the infected cells were measured by Western blotting, with b-actin as internal
control. C: Antiviral response of IFN-a, RBV, and IFN-l in short-term infected culture. Huh-7.5 cells were infected with cell cultureederived MOIZ 0.1 HCV
and treated with IFN-a, RBV, or IFN-l, alone or in combination. The treatment was given every 96 hours (arrows). Antiviral activity was determined by
measuring Renilla luciferase activity of cell lysates. D: Antiviral response of 2.5  IC90 IFN-a, 40 mg/mL RBV, and 10  IC90 IFN-l in persistently infected
culture. Arrows indicate treatments. To show the partial inhibition of HCV replication by IFN-a and RBV after ﬁve consecutive treatments (37 days), viral titer
is graphed in greater detail at the left. E and F: HCV Core protein (brown) was detected by immunocytochemistry in 2-day-infected culture (E) and HCV Coreþ
cells (F) were counted in 10 different high-power ﬁelds and compared with untreated controls. G and H: HCV Core protein was detected in persistently infected
culture (G) and HCV Coreþ cells (H) were counted in 10 different high-power ﬁelds and compared with untreated controls. Data are expressed as means  SD.
**P < 0.01, ***P < 0.001, and yP < 0.0001. Original magniﬁcation, 40 (E and G). hpf, high-power ﬁeld (40).
HCV Infection Impairs IFN-a Signalingfound that the IC90 for IFN-a, 100 IU/mL, was equivalent to
10 ng/mL of IFN-l (Supplemental Figure S3A). This result is
in agreement with published data.24 The antiviral treatment
response of IFN-a, RBV, and IFN-l in the HCV-infected
culture was examined over 37 days. Huh-7.5 cells infected
with JFH-DV3-Rluc recombinant virus showed increased
Renilla luciferase expression (Figure 2A). HCV infectionThe American Journal of Pathology - ajp.amjpathol.orgselectively down-regulated the expression of the IFN-a re-
ceptor, IFNAR1, but not of the IFN-l receptor (Figure 2B).
The HCV-infected culture was more sensitive to the IFN-
aþRBV combination treatment, but relatively insensitive to
either agent singly (Figure 2, C and D). Infected cells treated
with IFN-aþRBV or with IFN-aþIFN-l exhibited a
decrease in Renilla luciferase activity, which fell to below the219
Figure 3 HCV replication induces ER stress and an autophagy response. A: Uninfected (HCV) and infected (HCVþ) Huh-7.5 cells were transfected with
ATF6eﬁreﬂy luciferase reporter plasmid using FuGENE 6 transfection reagent. Luciferase activity in the cell lysates was measured over 10 days. B: Acridine
Orange staining shows the induced autophagy response in Huh-7.5 cells infected with HCV. Cells without autophagy show green ﬂuorescence. Cells with
autophagy show accumulation of orange-red cytoplasmic autophagic vacuoles. C: Induction of autophagy in the infected cells at different time points was
assessed by measuring autophagy-related proteins by Western blotting. D: The level of p62 (brown cytoplasmic staining) in persistently infected cells was
measured by immunohistochemistry. E: The p62þ cells in 10 different high-power ﬁelds (40) were counted at 3, 8 and 14 days and compared with uninfected
control (Huh-7.5). F: TEM analysis of ultrastructure of uninfected (Huh-7.5) and persistently infected (Huh-7.5þHCV) hepatocytes. Representative high-power
micrographs of autophagic vacuoles (AVs) present in the persistently infected cells (white arrow) show atypical double-membrane AVs (black arrow). Boxed
regions are shown at higher magniﬁcation in the panel to the right. G: During TEM studies, 10 cytoplasmic ﬁelds in a grid were captured randomly in each cell.
AV numbers per ﬁeld per cell were compared between uninfected and persistently infected cells. Data are expressed as means  SD. *P < 0.05; yP < 0.0001.
Original magniﬁcation: 40 (B and D). m, mitochondria.
Chandra et aldetection limit after 9 days (Figure 2C), as well as a decrease
in HCV RNA level (data not shown). The antiviral effect of
IFN-aþRBV was examined at multiple time points over 37
days. Results of three different measurements revealed that
IFN-a, RBV, and IFN-aþRBV all inhibited HCV replication
(P < 0.0001), but did not clear the virus (Figure 2D),
indicative of a persistently infected state. Using a HCV
subgenomic replicon model, we have previously observed
that IFN-l has marked antiviral activity in IFN-aeresistant
cell strains (unpublished data). We therefore compared the220antiviral activity of IFN-l with that of IFN-aþRBV using
our persistently infected Huh-7.5 cell culture model.
Consistent with our previous ﬁndings, Renilla luciferase
activity showed sustained and signiﬁcant inhibition in the
cultures treated with IFN-l1 (IL-29) (Figure 2D). Moreover,
IFN-aþIFN-l inhibited HCV replication to a greater extent
than either single agent alone, and levels at days 31 and 37
were below the assay detection limit. The luciferase-based
HCV replication assay results were conﬁrmed by measuring
HCV RNA levels by RT-qPCR, using primers targeted to theajp.amjpathol.org - The American Journal of Pathology
Figure 4 Persistent HCV replication impairs IFN-aeinduced phosphor-
ylation of STAT1 and STAT2 proteins, their nuclear translocation, and ISRE-
luciferase promoter activation. A: Uninfected (HCV) and infected cells
(HCVþ) were treated with 0, 0.1 IC90, 1 IC90, and 10 IC90 IFN-a for 30
minutes. Equal protein amounts were separated on SDS-PAGE gels, and
Western blotting analysis was performed using antibodies to p-STAT1,
STAT1, p-STAT2, STAT2, and b-actin. B: Phosphorylation of STAT proteins in
the persistently infected cells without or with IFN-a over 38 days was
measured 30 minutes after treatment by Western blotting. C: HCV-infected
cells were treated with 2.5  IC90 IFN-a or 10  IC90 IFN-l. Five consecu-
tive treatments (T1 to T5) were given, and STAT protein levels were measured
30 minutes after each treatment by Western blotting. D: IFN-a induced
STAT1 and STAT2 activity in uninfected and infected Huh-7.5 cells. An equal
number of uninfected and infected cells were transfected with ISRE-
luciferase plasmid. After 3 hours, cells were treated with 2.5  IC90 IFN-a;
on the next day, cells were lysed and luciferase activity was measured. The
presence of HCV replication was associated with signiﬁcantly reduced ISRE-
luciferase promoter activity. E: Nuclear translocation of pSTAT1-GFP and
pSTAT2-GFP in the uninfected (HCV) and persistently infected (HCVþ) cell
culture over 120 minutes was monitored by ﬂuorescence microscopy. Data
are expressed as means  SD. **P < 0.01. Original magniﬁcation: 40 (E).
HCV Infection Impairs IFN-a Signaling50 UTR (data not shown). The antiviral activity of IFN-a and
RBVwas also conﬁrmed by immunostaining of infected cells
before and after treatment, using a monoclonal antibody to
HCVCore protein in both short-term infected (Figure 2, E and
F) and persistently infected culture (Figure 2, G and H). The
immunostaining results were in agreement with the Renilla
luciferaseebased results, conﬁrming the sustained antiviral
activity of IFN-l against persistent HCV infection.
IL-28A/B also inhibited HCV replication in the persis-
tently infected cell culture in a similar capacity as IL-29
(data not shown). However, neither IFN-a nor IFN-aþRBV
cleared HCV replication in our persistently infected cell
culture model. Having determined that 100 IU/mL IFN-a is
equivalent to 10 ng/mL IFN-l, we compared the antiviral
effects of the two interferons separately, with persistently
infected cells treated with 2.5  IC90, 5  IC90, or 10 
IC90 of IFN-a or IFN-l. The antiviral effect was compared
over three consecutive treatments by the measurement of
Renilla luciferase and Core protein immunostaining. Results
of both assays (Supplemental Figure S3, B and D)
conﬁrmed that the antiviral effect of IFN-l was signiﬁcantly
stronger than IFN-a when both were used at equivalent
concentrations (P < 0.01, P < 0.001, and P < 0.0001).
HCV Core protein expression was absent in 10  IC90 IFN-
letreated cells, but not in 10  IC90 IFN-aetreated cells
(Supplemental Figure S3, BeD). At equivalent 10  IC90
concentration, IFN-l showed signiﬁcantly stronger inhibi-
tion and HCV clearance, compared with IFN-a.
The impaired clearance of HCV by IFN-a was not related
to a lack of biological activity, because the same IFN-a
preparation tested against an S3-GFP stable replicon cell line
exhibited signiﬁcant concentration-dependent antiviral ac-
tivity (Supplemental Figure S3E). There is a possibility that
long-term passaged virus-infected cells could have selected a
population of cells that is less responsive to IFN-a. To
address this concern, we prepared a cured cell line by
removing HCV, using repeated treatment with a combination
of two siRNAs (si321 and si359). The expression of IFN
receptors (mainly IFNAR1 and IFNlR) and JAKeSTAT
signaling (mainly STAT1 and STAT2) in the cured cell line
was restored to a level similar to that in the uninfected Huh-
7.5 cells. Reinfection of the same cured cell line with HCV
exhibited down-regulated expression of IFNAR1 and
impaired JAKeSTAT signaling (Supplemental Figure S4).
Persistently HCV-Infected Huh-7.5 Cell Culture
Develops ER Stress and Autophagy Response
We have previously shown that initiation of the ER stress
response in cells after HCV infection activates IRE1a,
PERK, and p-eIF2a.9 In the present study, ATF6-luciferase
activity showed that persistently HCV-infected culture also
induced a chronic ER stress response. Persistently infected
cells exhibited signiﬁcantly higher ATF6-luciferase activity,
compared with uninfected culture, over 10 days (Figure 3A).
Recent reports indicate that a cellular autophagy response isThe American Journal of Pathology - ajp.amjpathol.orgactivated secondary to ER stress as a cell-survival defense
mechanism.25,26
We also investigated whether persistent HCV replication
can induce the formation of autophagosomes, which then
progress to autophagolysosomes through fusion with acidic
lysosomes. We used Acridine Orange staining to examine
this process (Figure 3B). There was a signiﬁcant increase in
the number of orange-colored autophagolysosomes in HCV-
infected cells (Supplemental Figure S5), but the uninfected
Huh-7.5 cells exhibited cytoplasmic and nuclear green
ﬂuorescence without induction of autophagy (Figure 3B).221
Figure 5 Persistent HCV replication results in down-regulation of IFNAR1. A: HCV infection selectively down-regulates the IFNAR1 receptor. HCV-infected
cells repeatedly treated with 2.5  IC90 IFN-a or 10  IC90 IFN-l. Five consecutive treatments (T1 to T5, day 13 to day 37) were given, and after each
treatment the expression of IFNAR1, IFNAR2, and IL10Rb (IFNlR) was measured by Western blotting, with b-actin as loading control. B: Uninfected Huh-7.5
cells (HCV) were repeatedly treated with IFN-a, and IFNAR1 was measured at the ﬁve time points by Western blotting, with b-actin as loading control. C:
Overexpression of IFNAR1 by transient transfection increased the IFN-a antiviral response against HCV in the infected cell culture (P < 0.02). Antiviral action
of IFN-a was assessed by measuring Renilla luciferase activity 48 hours after treatment and compared with untreated controls. D: The surface expression of
IFN-a (IFNAR1), IFN-g (IFNgR1), and IFN-l (IL10Rb) receptors in uninfected and HCV-infected cells was evaluated by confocal microscopy. E: The expression
of IFNAR1, IFNgR1, and IL10Rb in normal (HCV) and persistently infected (HCVþ) Huh-7.5 cells was quantiﬁed by FACS analysis. Cells incubated with
secondary antibody were used as an experimental control. Percentages indicate the proportion of cells expressing IFN receptors. Data are representative of
three independent experiments. F: Quantitative expression of IFNAR1, IFNgR1, and IFNlR was determined by FACS analysis. Data are expressed as means  SD.
*P < 0.05, **P < 0.01, and yP < 0.0001. Original magniﬁcation: 60 (D). Ab, antibody; 1, primary; 2, secondary.
Chandra et alInduction of an autophagy response in the persistently
HCV-infected culture was examined using assays described
previously.20 Among these, LC3 is used as a speciﬁc marker
for induction of autophagy; the processing of LC3-I into
LC3-II is assessed by Western blotting. Infected cells were
harvested at 3, 8, and 14 days and processing of LC3-I into
LC3-II was examined. Induction of autophagy and conver-
sion of LC3-1 into LC3-II was increased in the infected cells
at 8 and 14 days (Figure 3C). The protein levels for one of
the critical autophagy genes, beclin 1 (BECN1), was also
induced in the persistently infected cells at 8 and 14 days
(Figure 3C and Supplemental Figure S6). The expression of
p62 protein was reduced signiﬁcantly in the infected cells in
a time-dependent manner, which indicated that HCV repli-
cation induced an autophagy response that selectively
degraded p62 protein (Figure 3, D and E). The presence of
HCV-induced autophagic vacuoles and the ultrastructure
of Huh-7.5 cells with or without 14 days of virus infection
were examined by TEM-based ultrastructural analysis. We
quantiﬁed double-membrane autophagosomes by counting
10 HCV-infected and 10 uninfected Huh-7.5 cells using
electron microscopy (Figure 3F). Signiﬁcantly higher
numbers of autophagic vacuoles were present in the
persistently infected cells, compared with uninfected cells222(Figure 3G). Taken together, these results provide evidence
that HCV infection results in ER stress and autophagy
responses.
Chronic ER Stress and the Autophagy Response Impair
the Antiviral Action of IFN-a
A series of reports using stable replicon cell lines have
provided evidence that activation of JAKeSTAT signaling
is critical for the successful antiviral effects of IFN-a.9,27,28
Activation of JAKeSTAT signaling can be detected by the
measurement of IFN-aeinduced STAT1 and STAT2
phosphorylation. Phosphorylation of STAT1 and STAT2
after 30 minutes of treatment with 10  IC90 IFN-a was
blocked in persistently infected cells for up to 38 days
(Figure 4, A and B). Total STAT1 levels varied over the
time course, but total STAT2 was essentially unaffected
(Figure 4B). The levels of STAT1 and STAT2 proteins in
infected cells were also measured by Western blotting, after
ﬁve consecutive treatments (T1 to T5) with IFN-a or IFN-l.
The levels of p-STAT1 and p-STAT2 were rescued when
the infected cells were treated with IFN-l, but were unde-
tectable after treatment with IFN-a (Figure 4C). IFN-
aemediated activation of STAT1 and STAT2 proteins wasajp.amjpathol.org - The American Journal of Pathology
Figure 6 Persistent HCV infection impairs
antiviral action of IFN-a via down-regulation of
IFNAR1. A: Experimental design. Persistently
infected Huh-7.5 cells (45 days of infection)
received two consecutive treatments (T1 and T2)
with 2.5  IC90 IFN-a, and then HCVþ and HCV
cells were sorted by using FACS. B: Detection of
HCV in untreated and IFN-aetreated cells. HCV
Core protein was labeled by immunoﬂuorescence
technique using green ﬂuorescence secondary
antibody and then detected by ﬂow cytometry.
Persistently infected cells (Huh-7.5) and cells with
only secondary antibody (Huh-7.5 þ 2 Ab) were
used as controls. C: After IFN-a treatment, HCV
(IFN-aesensitive) and HCVþ (IFN-aeresistant)
cell populations were separated by FACS. D: The
level of IFN receptors between IFN-aesensitive
and resistant populations was measured by West-
ern blotting, with b-actin as internal control. PE,
phycoerythrin.
HCV Infection Impairs IFN-a Signalingveriﬁed using an ISREeﬁreﬂy luciferase assay. ISRE pro-
moter activity was signiﬁcantly reduced (P Z 0.01) in
persistently infected cells (Figure 4D). To determine
whether the defective STAT1 and STAT2 phosphorylation
impairs nuclear translocation of STAT1 and STAT2,
pSTAT1-GFP and pSTAT2-GFP plasmids were transiently
transfected into uninfected and infected Huh-7.5 cells. The
impaired nuclear translocation of STAT1 and STAT2 was
observed only in cells persistently infected with HCV
(Figure 4E).
We examined whether the loss of cell surface expression
of IFNAR1 affects JAKeSTAT signaling in persistently
infected cells. The expression level of IFNAR1 in the
persistently HCV-infected cell culture system was examined
by Western blotting. The levels of IFNAR1, IFNAR2, and
the IFN-l receptor in the persistently infected Huh 7.5 cells
were also measured, by Western blotting, after ﬁve
consecutive treatments (T1 to T5) with 2.5  IC90 IFN-a or
10  IC90 IFN-l (Figure 5A). The reduction of IFNAR1
expression was greater in the untreated HCV-infected cul-
ture (Figure 2B) than in the IFN-aetreated HCV-infected
culture (Figure 5A), because IFN-a treatment signiﬁcantly
inhibits the HCV replication that could have restored the
expression level of IFNAR1. This conclusion was con-
ﬁrmed by measuring the levels of IFNAR1 between un-
treated and treated HCV-infected culture (Supplemental
Figure S3F). The levels of IFNAR1 decreased over time,
and this could be reversed by treatment with IFN-l but not
with IFN-a. The expression of IFNAR1 did not change inThe American Journal of Pathology - ajp.amjpathol.orguninfected Huh-7.5 cells that were repeatedly treated with
IFN-a for 37 days (Figure 5B), eliminating the possibility
that the loss of IFNAR1 expression was due to anti-
proliferative effects of IFN-a. Furthermore, re-expression of
ectopic IFNAR1 in the persistently infected cells signiﬁ-
cantly increased the antiviral activity of IFN-a (Figure 5C).
The effect of HCV replication in the persistently infected
cell culture on the cell surface expression of IFNAR1,
IFNgR1, and IL10Rb (IFNlR) was examined by confocal
microscopy at day 37 (Figure 5D). The above-mentioned
type I, type II, and type III interferon receptors were ex-
pressed constitutively in uninfected cells; in persistently
infected cells, however, IFNAR1 expression was decreased
to a signiﬁcantly greater extent than the other two receptors
(Figure 5, E and F).
We further veriﬁed our hypothesis, that the lack of cell
surface expression of IFNAR1 might cause the IFN-a
resistance, by analyzing HCVþ and HCV cell populations
after ﬂow sorting (Figure 6). Persistently infected cells were
treated with 2.5  IC90 IFN-a on days 47 and 51, and cell
sorting after HCV Core protein staining was performed on
day 54 (Figure 6A). Treatment with IFN-a induced HCV
clearance to 45% at P4 (compared with 17% for untreated
cells); nearly one third of IFN-aetreated infected cells (19%
out of 64%) did not clear HCV at P5 (Figure 6B). The
speciﬁcity of sorted cells was veriﬁed; sorted cells were
exclusively either HCV (IFN-a sensitive) or HCVþ (IFN-
a resistant) (Figure 6C). Protein extracts of ﬂow-sorted
HCVþ and HCV cell populations were examined for the223
Figure 7 Impaired RBV uptake and reduced expression of nucleoside
transporters in an IFN-a- and RBV-resistant cell strain. A: [3H]Cytidine and
[3H]RBV uptake assay. Persistently infected cells were repeatedly treated
with IFN-a and RBV for 37 days to produce an IFN-aþRBVeresistant strain
of the Huh-7.5 cell line. Persistently infected Huh-7.5 cells were used as a
control. Cells were incubated in medium containing [3H]RBV and [3H]
cytidine (as a control). [3H]RBV uptake was increased, relative to control
(P Z 0.02), as determined by scintillation counting. The data were nor-
malized to account for cell numbers. B: Western blot analysis of nucleoside
transporters (ENT1 and CNT1) using equal amount of protein lysates from
uninfected Huh-7.5 cells, HCV-infected Huh-7.5 cells, and IFN-aþ
RBVeresistant persistently infected cells at ﬁve treatment times (T1 to T5,
day 13 to day 37). C: The level of transporters (ENT1 and CNT1) after
prolonged IFN-a and IFN-aþRBV treatment in uninfected cells. Huh-7.5
cells received ﬁve consecutive treatments (day 13 to day 37) of IFN-a
and IFN-aþRBV, and the transporter levels were measured by Western
blotting. Data are expressed as means  SD. *P < 0.05.
Chandra et alexpression of IFNAR1, IFNgR1, IFNlR, and b-actin by
Western blotting (Figure 6D). The IFN-aeresistant cells
had a notably lower level of IFNAR1 than the IFN-ae
sensitive cells. The faint IFNAR1 band seen in the resistant
cells (Figure 6D) could be due to the presence of 6% of
HCV cells separated by ﬂow sorting. The expression of
IFNgR1, IFNlR, and b-actin between the two cell pop-
ulations was similar.
Reduced Expression of Nucleoside Transporter and
Impaired RBV Uptake in Persistently Infected Cells
RBV plays a crucial role in the treatment of chronic HCV
infection, although the mechanism or mechanisms by which
many patients develop resistance to RBV are not well un-
derstood. Ibarra and Pfeiffer13 reported that reduced uptake
by HCV-infected cells contributes to an impaired antiviral
response. They demonstrated that RBV uptake was reduced
in the infected cells, although transporter levels were unal-
tered. In the present study, we investigated whether reduced
cellular import of RBV could have caused its treatment
failure in persistently HCV-infected cells. Persistently
infected cells showed 26% less RBV uptake with respect to
cytidine (used as a control), but the difference was not
statistically signiﬁcant. Uptake was reduced by up to 62% in
the IFN-aþRBVeresistant cell strain (Figure 7A). The
signiﬁcant reduction of RBV uptake in the IFN-aþRBVe
resistant cell strain (P Z 0.02) could have been due to the
fact these cultures had previously been exposed to 40 mg/
mL RBV. RBV is transported into cells via the nucleoside
transporters ENT1 and CNT1.29 The expression of the
ENT1 and CNT1 nucleoside transporters in the infected and
uninfected cells was examined by Western blotting. The
expression of ENT1 and CNT1 was notably reduced in the
IFN-aþRBVeresistant cells, compared with the HCV-
infected cells (Figure 7B). The expression level of ENT1
and CNT1 in uninfected Huh-7.5 cells did not change
signiﬁcantly when treated with IFN-a or with IFN-aþRBV
(Figure 7C).
Induction of ER Stress and Autophagy Response
Selectively Down-Regulates IFNAR1
To investigate the relationship between ER stress and
autophagy and IFN receptors, we ﬁrst induced ER stress and
autophagy response with the known inducers TG and Torin
1, respectively, in uninfected Huh-7.5 cells (Figure 8, A and
C). ER stress and autophagy induction impaired expression
of type 1 IFN receptors (IFNAR1 and IFNAR2) (Figure 8, B
and D). We performed TG and Torin 1 titration experiments
in HCV-infected and uninfected Huh-7.5 cells to compare
IFNAR1 expression by Western blotting. Degradation of
IFNAR1 was signiﬁcantly higher if infected cells were
treated with either TG or Torin 1, indicating that the
mechanisms of IFNAR1 regulation are linked to ER stress
and autophagy response associated with HCV infection224(Figure 8E). In another approach, we veriﬁed that knock-
down of the autophagy-related gene ATG7 and the ER stress
kinase gene PERK (EIF2AK3) by siRNA rescued the ex-
pression of IFNAR1 in persistently infected cells (Figure 8,
F and G). Taken together, these results provide evidence for
the relationship of ER stress and autophagy with IFNAR1
down-regulation.ajp.amjpathol.org - The American Journal of Pathology
Figure 8 Induction of ER stress and autophagy response selectively down-regulated the expression of IFN-a receptor 1 measured by Western blotting. A:
Huh-7.5 cells were treated with TG, a known ER stress inducer, and the unfolded protein responseerelated proteins BiP, IRE1a, and peIF2a were measured. B:
The level of IFN receptors with increasing concentration of TG was measured. C: Huh-7.5 cells were treated with increasing concentration of Torin 1, a known
autophagy inducer, and the autophagy response was assessed by measuring LC3II and p62 levels. D: The level of IFN receptors with increasing concentration of
Torin 1 was measured. E: TG and Torin 1 titrations in HCV-infected cells and uninfected cells. IFNAR1 down-regulation was greater in HCV-infected cells treated
with autophagy inducer (Torin 1) or ER stress inducer (TG). F: Knockdown by siRNA of ATG7, one of the autophagy genes, rescued IFNAR1 level. Increasing
concentration of siATG7 was transfected in the persistently infected Huh-7.5 cells. After 72 hours, cells were lysed and the level of IFN receptors was measured.
G: Silencing PERK restores the expression of IFNAR1. siPERK in increasing concentrations was transfected to the persistently infected Huh-7.5 cell. After
72 hours, cells were lysed and the expression of IFNAR1 and IFNlR was measured.
HCV Infection Impairs IFN-a SignalingSilencing of ER Stress and the Autophagy Response
Overcome IFN-a Resistance in Persistently Infected
Cells
To further investigate the role of ER stress and the induced
autophagy response in effecting defective JAKeSTAT
signaling and IFN-a resistance, persistently HCV-infected
cells were pretreated with inhibitors of either ER stress
(PBA) or autophagy (HCQ) for 24 hours; the antiviral ac-
tivity of IFN-awas determined at 72 hours after treatment, by
measuring Renilla luciferase activity. Both PBA and HCQ
signiﬁcantly inhibited HCV replication in a dose-dependent
manner (Figure 9, A and B). We examined whether treat-
ment of the HCV-infected culture with PBA or HCQ in
combination with IFN-a, or with IFN-aþRBV, can clear
HCV replication effectively. IFN-a signiﬁcantly inhibited
HCV replication in the presence of either PBA or HCQ
(Figure 9, C and D). The results were conﬁrmed byThe American Journal of Pathology - ajp.amjpathol.orgmeasuring HCV Core protein expression after immuno-
staining (Figure 9, E and F). The concentrations of PBA and
HCQ used in the present study were not toxic to cells, as
determined using an MTT assay (Figure 9G). In a different
approach, genes for three cellular ER stress sensors (PERK,
IRE1a, and ATF6) and one of the autophagy genes, ATG7,
were silenced using siRNA; silencing was conﬁrmed by
Western blotting (Figure 9H). The siRNAs were transfected
into the HCV-infected cell culture and, after 3 hours, cells
were treated with 2.5 IC90 IFN-a and 40 mg/mL RBV. The
antiviral activity of IFN-a and of IFN-aþRBV improved
signiﬁcantly after these genes were silenced (Figure 9I).
The silencing of ATG7 inhibits autophagy, which is why it
restores the expression of IFNAR1. We observed that
inhibiting autophagy by silencing ATG7 to some extent also
inhibits HCV replication and Renilla luciferase activity. This
is consistent with previous report that inhibition of autophagy
inhibits HCV replication.17 Cells transfected with irrelevant225
Figure 9 Inhibition of ER stress and autophagy response by chemical inhibitors signiﬁcantly improves the IFN-a and RBV antiviral effect against HCV in
persistently infected cells. A and B: Pretreatment with ER stress inhibitor (PBA) or autophagy inhibitor (HCQ) signiﬁcantly inhibits HCV replication. Equal
numbers of persistently infected cells were treated with different concentrations of PBA (0 to 10 mmol/L) and HCQ (0 to 40 mmol/L) overnight. The next day,
cells were incubated with fresh medium; after 72 hours, HCV replication was assessed by measuring Renilla luciferase activity. CeE: Pretreatment with PBA and
HCQ signiﬁcantly improved antiviral activity of IFN-a, alone or in combination with RBV, inhibiting HCV replication. Equal numbers of persistently infected
cells were treated overnight with 10 mmol/L PBA or 20 mmol/L HCQ. The next day, cells were incubated with fresh medium and treated with 250 IU/mL IFN-a
alone or in combination with 40 mg/mL RBV. After 72 hours, HCV replication was assessed by measurement of Renilla luciferase activity (C and D) and HCV Core
protein expression by immunostaining (E). F: HCV Coreþ cells in 10 different high-power ﬁelds (40) were counted and compared with untreated control. G:
Cell viability with PBA or HCQ treatment was assessed by MTT assay. Huh-7.5 cells were treated overnight with different concentrations of PBA (0 to 60 mmol/
L) or HCQ (0 to 100 mmol/L). After 72 hours, MTT assay was performed. The IC50 (dashed line) of PBA and of HCQ is indicated by an arrow. H and I: Silencing
of ER stress sensors (PERK, IRE1a, ATF6) and the autophagy gene (ATG7) signiﬁcantly inhibited HCV replication and also improved the antiviral action of IFN-a
and RBV. Equal numbers of persistently infected cells were split in a six-well plate. The next day, cells were transfected with the respective siRNAs, mock
transfection, or siIRR. After 3 hours of transfection, cells were treated with IFN-a alone or in combination with RBV. After a further 72 hours, a portion of the
cells was lysed, and silencing efﬁcacies of the siRNAs were determined by Western blotting (H) and HCV replication was assessed by measuring Renilla
luciferase activity (I). All experiments were performed in triplicate. Data are expressed as means  SD. **P < 0.01, ***P < 0.001, and yP < 0.0001.
Chandra et alsiRNA (siIRR) also showed some reduction in Renilla
luciferase activity, but these differences were not statistically
signiﬁcant in comparison with ATG7-transfected cells
(Figure 9I). These experiments are suggestive of a causal
relationship between ER stress and the autophagy response
and the mechanisms underlying the HCV resistance to IFN-
aþRBV. Based on these results, we propose a model of how
HCV replication in the persistently infected cell culture
model impairs the IFN-a and RBV antiviral mechanism
(Figure 10).226Discussion
We developed a stable and persistently HCV-infected Huh-
7.5 cell culture system to study long-term antiviral treatment
response using IFN-a, RBV, and IFN-l. Intracellular HCV
replication and virus secretion in the persistently infected
cell culture is stable for an extended period (more than a
year). We showed that a very high percentage of cells in the
culture are infected with HCV, which can be passaged over
a number of generations. We propose that this cell cultureajp.amjpathol.org - The American Journal of Pathology
Figure 10 Schematic of impairment of IFN-a and RBV signaling in
persistently HCV-infected culture.
HCV Infection Impairs IFN-a Signalingmodel can be used to address a number of questions related
to virusehost interaction in the persistence of HCV and
pathogenesis.
Various host-related and virus-related factors have been
proposed to be responsible for the mechanisms of HCV
resistant to IFN-a and RBV.12 It has been observed in
clinical studies that chronic HCV patients with a high viral
load have a signiﬁcantly lower sustained virologic response
to IFN-aþRBV antiviral therapy,30e32 but the mechanism
or mechanisms underlying the resistance are not well un-
derstood. Our cell culture study results indicate that HCV
replication in the persistently infected cell culture cannot be
completely eliminated by IFN-a or RBV alone, nor even
with the IFN-aþRBV combination. In contrast, IFN-l (IL-
29) treatment at an equivalent concentration achieved a
sustained antiviral response, leading to viral clearance in the
persistently infected cell culture.
These results are quite different from those of studies
performed using subgenomic replicon cell lines or acutely
HCV-infected cell culture models. In our persistently HCV-
infected cell culture, expression of nucleoside transporters
(ENT1, CNT1) is reduced, which explains why RBV
treatment alone was not effective for clearing HCV repli-
cation in this cell culture. To ﬁnd an explanation why HCV
replication is not eliminated even after repeated treatment
with IFN-a, we looked at the modulation of the cell surface
expression of IFNAR1 (type I IFN receptor). We found that
the HCV-induced ER stress and autophagy response selec-
tively repair type I interferon signaling, but not type III. This
ﬁnding is supported by evidence that ER stress down-
regulates IFNAR1 expression.33
A number of studies have shown that the unfolded protein
response due to ER stress and the autophagy response both
play an important role for HCV replication and for sup-
pression of antiviral signaling in infected cells.9,33e36 He-
patic ER stress37 and an increased autophagic response38
have been reported in liver of chronically HCV-infected
patients, relative to healthy liver. The present study dem-
onstrates a causal link between chronic ER stress and
autophagy and the negative expression of IFNAR1 and
impaired antiviral response. This hypothesis is supported by
results indicating that inhibiting the ER stress and auto-
phagy responses improved the antiviral response of IFN-
aþRBV. The mechanisms of HCV persistence in the
infected culture involve new rounds of infection, as well as
carriage from previously infected cells. We suspect, there-
fore, that HCV replication is not uniform in the culture,
which could explain why a signiﬁcant number of persis-
tently infected cells have cleared HCV after IFN-a treatment
but a portion of the infected cell population remains
nonresponsive to IFN-a. In support of this notion, IFNAR1
expression was drastically low in the sorted IFN-aeresistant
cell population, compared with IFN-aesensitive cells. This
has been veriﬁed for other virus models in which only
high doses of active or inactive HSV induce IFNAR1
phosphorylation and degradation.39 Based on these data, weThe American Journal of Pathology - ajp.amjpathol.orgpropose that infected cells supporting only a very high level
of viral replication experience a loss of cell surface ex-
pression of IFNAR1. We also propose that this persistently
HCV-infected cell culture model can be used to investigate
the signiﬁcance of other mechanisms described in the
literature relating HCV resistance to IFN-a.
Interestingly, we found that IFN-l has a strong and sus-
tained antiviral effect against HCV, compared with IFN-a
and RBV. IFN-l, alone or in combination with IFN-a,
cleared HCV replication in the persistently HCV-infected
cell culture model. These results suggest that type III IFN
(IFN-l) may be important in controlling HCV infections in
humans. The relevance of this result is supported by a
number of clinical studies indicating that IL-28B genotype
assessment provides a predictor of sustained virologic
response to IFN-aþRBV therapy. The underlying mecha-
nisms of how the IL-28B genotype controls HCV clearance
are not clear. The IFN-l family includes at least three
members: IFN-l1, IFN-l2, and IFN-l3, which are encoded
by the IL-29, IL-28, and IL-28B genes (IFNL1, IFNL2, and
IFNL3, respectively). We speculate that the production of
IFN-l in chronically infected HCV patients may be linked
to IL-28B gene polymorphisms. This hypothesis is sup-
ported by reports that IFN-l production is regulated by IL-
28B gene polymorphisms.40,41
Our present results are also supported by reports indi-
cating that the IFN-l antiviral response against HCV is
stronger than that of IFN-a.24,42 Rice and colleagues42 showed
that IFN-l has a distinct gene induction signature and signal
transduction proﬁle against HCV. A recent study by Bar-
tenschlager and colleagues24 showed that persistently infected
cell culture is resistant to IFN-a and that IFN-l showed a
stronger antiviral response than IFN-a. Lambda interferons are227
Chandra et alproduced during HCV infection and are therefore considered
to play an important role in the innate immune response against
HCV. How IFN-l1 contributes to the antiviral control of
chronic HCV infection in humans is unclear. Our results show
that a persistently infected cell culture model develops resis-
tance to IFN-a and RBV because of defective JAKeSTAT
signaling and impairedRBVuptake. The fact that IFN-l clears
HCV replication in the persistently infected cell culture war-
rants further studies to elucidate the novel antiviral mecha-
nisms of IFN-l against HCV.Acknowledgments
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